findmyKOL
Clinical trialNCT01931046CompletedPhase 1/PHASE2Interventional

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

SponsorMomotaro-Gene Inc.Enrollment28Localized Prostate Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety and effectiveness of AD5-SGE-REIC/Dkk-3 in patients with localized prostate cancer.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Ucsd Moores Cancer Center

    San Diego, California, United States

  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

  • the Methodist Hospital Research Institute

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ad5-SGE-REIC/Dkk3
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Oct 2013
Primary completion
6 Jul 2018
Completion
31 Mar 2020
Last update posted
4 Sept 2020
Registered enrollment
28
Registry id
NCT01931046

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.